Furthermore, sorafenib indirectly inhibits tumor cell proliferation by suppressing tumor angiogenesis via targeting c-Kit, FLT-3, VEGFR-2/3, PDGFR-β, and other tyrosine kinases, which are activated in tumor angiogenesis. This evidence concerns the gene KDR and neoplasm.